Focused On-demand Library for Cell division control protein 6 homolog

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q99741

UPID:

CDC6_HUMAN

Alternative names:

CDC6-related protein; Cdc18-related protein; p62(cdc6)

Alternative UPACC:

Q99741; Q8TB30

Background:

Cell division control protein 6 homolog, known by alternative names such as CDC6-related protein, Cdc18-related protein, and p62(cdc6), plays a pivotal role in the initiation of DNA replication. It is also integral to checkpoint controls that ensure DNA replication is completed before mitosis is initiated, highlighting its critical function in cell cycle regulation.

Therapeutic significance:

Linked to Meier-Gorlin syndrome 5, a condition characterized by growth retardation, skeletal anomalies, and microcephaly, yet with normal intellect, the protein's gene variants suggest a therapeutic target. Understanding the role of Cell division control protein 6 homolog could open doors to potential therapeutic strategies for this syndrome.